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The aim was to study the effect of compliance with guidelines on local recurrence (LR)-free survival in patients treated for ductal
carcinoma in situ (DCIS). From January 1992 to December 2003, 251 consecutive patients had been treated for DCIS in two
hospitals in the North Netherlands. Every case in this two-hospital sample was reviewed in retrospect for its clinical and pathological
parameters. It was determined whether treatment had been carried out according to clinical guidelines, and outcomes in follow-up
were assessed. In addition, all patients treated for DCIS in this region (n¼1389) were studied regarding clinical parameters, in order
to determine whether the two-hospital sample was representative of the entire region. In the two-hospital sample, 31.4% (n¼79) of
the patients had not been treated according to the guidelines. Positive margins were associated with LR (hazard ratio (HR)¼4.790,
95% confidence interval (CI) 1.696–13.531). Breast-conserving surgery and deviation from the guidelines were independent
predictors of LR (HR¼7.842, 95% CI 2.126–28.926; HR¼2.778, 95% CI 0.982–6.781, respectively). Although the guidelines
changed over time, time was not a significant factor in predicting LRs (HR¼1.254, 95% CI 0.272–5.776 for time period 1992–1995
and HR¼1.976, 95% CI 0.526–7.421 for time period 1996–1999). Clinical guidelines for the treatment of patients with DCIS have
been developed and updated from existing literature and best evidence. Compliance with the guidelines was an independent
predictor of disease-free survival. These findings support the application of guidelines in the treatment of DCIS.
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The main goal in the treatment of DCIS is the prevention of local
recurrences (LR). Standards regarding the optimal management
of patients with DCIS have been developed (Schwartz et al, 2000;
Morrow et al, 2002; Mokbel 2003; Sakorafas and Farley 2003;
Burstein et al, 2004). Mastectomy could be performed in cases with
multiple areas of DCIS and in cases with large areas of DCIS, of
a size that the lesion cannot undergo an oncologically and
cosmetically acceptable excision (X3cm (Sakorafas and Farley,
2003); X4cm (Mokbel, 2003)). Mastectomy could also be
considered in cases with positive margins after reasonable surgical
attempts of complete local excision or if it were the patient’s
preference and it may be indicated when breast irradiation is
contraindicated (e.g. in patients who are pregnant or have collagen
vascular disease). Breast-conserving surgery (BCS) could be
considered where DCIS is localised and if the area p4cm.
Removal of DCIS should be complete and margins should be at
least 1mm free of DCIS (Burstein et al, 2004). The addition of
radiotherapy following local excision benefits all groups of patients
with DCIS and is generally advised. Neither axillary-node
dissection nor sentinel node biopsy (SNB) is routinely indicated.
SNB could be considered in women undergoing mastectomy or
in women at higher risk of occult invasive disease (patients
with clinically palpable masses or areas of DCIS 44cm). Adjuvant
endocrine therapy could be considered after BCS with
radiotherapy to reduce the risk of ipsilateral recurrence and
contralateral disease, particularly in the case of oestrogen receptor-
positive DCIS (Morrow et al, 2002; Burstein et al, 2004).
The purpose of such retrospective study is to evaluate the effect
of compliance with existing clinical standards on LR-free survival
in patients treated for DCIS. To estimate the effect of compliance
with clinical standards in this two-hospital study, the clinical and
pathological parameters for every consecutive case of DCIS, in a
given period, were examined retrospectively. It was determined
whether treatment had been carried out according to the standards
existing at the time and the outcomes in follow-up were assessed.
PATIENTS AND METHODS
In the North Netherlands, the first guidelines for the treatment of
patients with DCIS were developed in 1992 by a cooperating group
of specialists in the field of breast cancer in the region (Otter,
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s1992). These clinical guidelines were based on evidence from
existing literature and guidelines by other groups and have been
updated every 2 or 3 years. According to the above-mentioned
guidelines and to those of 1994 (Otter, 1994), BCS is advised in the
case of a tumour smaller than or equal to 2cm and a simple
mastectomy in the case of a tumour larger than 2cm. It is essential
that BCS and mastectomy result in tumour-free margins. The 1996
guidelines (Otter, 1996) state that a complete surgical removal of
all DCIS with microscopic free surgical margins is advised.
Involvement of the deep margin after BCS is considered as a
positive margin. A simple mastectomy is the safest way and BCS
should consist of wide local excision with microscopic free
margins. Adjuvant radiotherapy is optional but should not replace
surgery for incomplete removal of DCIS. The 1998 (Otter, 1998)
and 2000 (Otter, 2000) guidelines advise BCS with standard
administration of radiotherapy for intermediately and poorly
differentiated DCIS (Grades 2 and 3) and a simple mastectomy if
no free margins can be achieved. If the excision is not complete in
the case of well-differentiated DCIS, a wait-and-see policy is
permitted if the patient is motivated, if there are no indications of
hereditary breast cancer, and if mammograms can be properly
reviewed. According to the 2003 guidelines (Otter, 2003), BCS and
postoperative radiotherapy is advised for all subgroups. Chest wall
radiation is advised if DCIS extends to the deep margin after a
simple mastectomy. A sentinel node procedure could be performed
in the case of tumours X5cm. Axillary lymph node dissection
(ALND) has not been recommended in any guideline since 1992
and the administration of tamoxifen or other hormonal therapy
has not yet been advised.
To investigate compliance with the guidelines and its effect on
LR, 251 consecutive patients from two hospitals were studied.
These patients had been treated for DCIS in the period January
1992 to December 2003 in the University of Groningen Medical
Center (UMCG) and the Martini Hospital (MH). The UMCG is the
only academic medical centre in the region and the MH is a large
teaching hospital.
Data were retrieved retrospectively from medical charts and also
from pathology and radiology reports. All analyses were performed
on anonymous data. The present study is in agreement with the
Dutch Law on the Conformity of Medical Treatment (WGBO). The
following data were available for all patients: age, menopausal
status, mode of detection, family history of breast cancer,
mammographic appearance and size, fine-needle aspiration
cytology, stereotactic large core needle biopsy or ultrasound
guided large core needle biopsy (SCNB), treatment modalities,
pathological size, pathological grade according to the European
Pathologist Working Group classification (Shoker and Sloane,
1999), surgical margins and follow-up. Mammography and
pathological characteristics were derived from radiology
and pathology reports. If data were missing, mammography
and pathological slides were re-evaluated. Surgical margins
o1mm were considered to be positive. LR was defined as
ipsilateral breast or chest wall recurrence of both DCIS and
invasive breast cancer. The date of last follow-up was November
2004. Compliance with guidelines was stated as follows: treatment
was classified as appropriate (guidelinesþ) if the interventions
undertaken were in agreement with the guidelines in operation at
the time of treatment, whereas deviations from the guidelines were
classified as inappropriate (guidelines ). Owing to changes in the
guidelines, the total study period is divided into three separate
time periods (1992–1995, 1996–1999 and 2000–2003).
Between January 1992 and December 2003, 1389 patients were
treated for DCIS in the North Netherlands, an area of 2.1 million
inhabitants. The main sources for cancer registration at the
Comprehensive Cancer Center North Netherlands (CCCN) are
the national computerised pathology databank (PALGA) and
the hospital discharge databank to which all Dutch hospitals
provide information annually on the discharge diagnoses of
patients admitted. Specially trained CCCN employees pros-
pectively register data regarding patients diagnosed with DCIS.
Within the CCCN district, there is one academic medical centre,
four teaching general hospitals and 12 nonteaching general
hospitals.
As there are no data available in the CCCN cancer registry on
tumour size and margin status, and because LR had only been
registered if the recurrence consisted of invasive disease, it was not
possible to evaluate all patients for treatment according to the
guidelines. Therefore, clinical data concerning this population of
patients treated for DCIS were used to determine whether the two-
hospital sample was representative for the total region of the North
Netherlands.
To evaluate the effect of compliance with existing guidelines,
patients were divided into an LR positive (LRþ) and an LR
negative (LR ) group. Univariate Cox regression analyses were
performed for each prognostic factor separately, considering the
time to the onset of LRs as the outcome. Hazard ratios (HRs) and
95% confidence intervals (CIs) were estimated. To test the
assumption of proportional hazards, an interaction term of a
prognostic variable and a time-dependent covariate were added to
each separate model (Klein and Moeschberger, 2003). A significant
effect of that interaction term denotes the presence of a time-
dependent effect and thus a violation of the proportional hazards
assumption. As a control for unmeasured differences in the study
period, due to changes in guidelines over time, we added the study
period as a factor in the multivariate Cox regression analysis.
Subsequently multivariate Cox regression analyses were per-
formed. The elimination of variables in a stepwise manner
identified the statistically significant predictors. LR-free survival
was analysed using Kaplan–Meier survival analysis and the log-
rank test. Patients were censored if they had died or otherwise
been lost to follow-up. A P-value of 0.05 was considered as
significant. All analyses were performed with program SPSS
version 12.01.
RESULTS
Clinicopathological characteristics of patients in the two-hospital
sample are summarised in Table 1. The median age of the total
study population was 57 years (range 32–85 years). In all, 49%
(n¼122) of all cases were detected by the Dutch Breast Cancer
Screening Programme. Nearly one-third of the women (n¼79)
had not been treated according to the guidelines operating in the
year of treatment. A total of 18 patients had positive margins after
final surgery.
BCS (HR¼10.328, 95% CI 2.907–36.693), positive margins
(HR¼4.790, 95%CI 1.696–13.531) and inappropriate treatment
(guidelines  (HR¼4.339, 95% CI 1.695–11.18)) were all char-
acteristics associated with LR in univariate analysis (Table 1).
There was no violation of the assumption of proportional hazards
regarding the outcome and any prognostic factor (unpublished
data). In Table 2, the independent predictors of LR after treatment
of DCIS are shown: BCS without radiotherapy (HR¼7.842, 95% CI
2.126–28.926) and deviation from the guidelines (HR¼2.778, 95%
CI 0.982–6.781). Although the guidelines changed with time, time
was not a significant factor in the Cox analysis (HR¼1.254, 95%
CI 0.272–5.776 for study period 1992–1995 and HR¼1.976, 95%
CI 0.526–7.421 for study period 1996–1999).
The median follow-up was 43 months (mean 49, range 10–120
months). Figure 1A shows that LR-free survival was better in
patients who had been treated according to the guidelines than in
patients who had been treated inappropriately (log rank 10.41,
P¼0.001). The 5-year LR-free survival in patients treated with
BCS, was 91% in patients who had been treated according to the
guidelines and 73% in patients who had not been treated so (log
rank 4.77, P¼0.029; Figure 1B).
Support for the application of guidelines in ductal carcinoma in situ
MAJ de Roos et al
1123
British Journal of Cancer (2005) 93(10), 1122–1127 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sIn Table 3, clinical data of patients treated in the two-hospital
sample are compared with data from the entire population of
patients in the North Netherlands. Patients in the two-hospital
sample had undergone fewer axillary staging procedures than
patients in the total region (w
2¼32.64; Po0.001). Information on
surgical management with regard to the entire population of
patients in the North Netherlands was available for 1221 of the
1389 women involved: less than half of the women (n¼525, 43.0%)
had BCS. Information on axillary surgical management was also
available for 1221 of the 1389 women involved: 299 women (24.5%)
had ALND or SNB.
Of all patients with LRs (n¼19) in the two-hospital sample,
seven patients had been treated according to the guidelines and 12
patients had been treated inappropriately. Of these 12 patients, five
had positive margins after final surgery, four had not received
adjuvant radiotherapy after local excision, two patients had not
undergone mastectomy, although their tumours were larger than
two centimetres, and one patient had undergone ALND.
DISCUSSION
Clinical guidelines reflect optimal management according to
existing views and literature, and have been introduced to reduce
inappropriate practice and to improve the quality of care (Lomas
et al, 1989; Grimshaw and Russell, 1993; Mann, 1996). In the North
Table 1 Clinico-pathological characteristics of patients of the two-hospital sample and local recurrence (Cox’s regression, univariate analysis)
Clinicopathological characteristic LR+ (n¼19) LR  (n¼232) HR 95% CI P-value
Age (years) (mean) 60.4 57.3 — — —
p40 years 2 (10.5) 10 (4.3) 2.800 0.645–12.152 0.169
440 years 17 (89.5) 222 (95.7) 1
Premenopausal 3 (15.8) 60 (25.9) 0.411 0.118–1.436 0.164
Postmenopausal 16 (84.2) 172 (74.1) 1
Screen detected 5 (26.3) 117 (50.4) 0.451 0.161–1.260 0.129
Other 14 (73.7) 115 (49.6) 1
Family history 3 (15.8) 57 (24.6) 0.685 0.199–2.356 0.549
No family history 16 (84.2) 175 (75.4) 1
FNAC 4 (21.1) 42 (18.1) 1.042 0.345–3.146 0.941
No FNAC 15 (78.9) 190 (81.9) 1
SCNB 3 (15.8) 105 (45.3) 0.428 0.121–1.512 0.188
No SCNB 16 (84.2) 127 (54.7) 1
Microcalcifications 8 (42.1) 61 (26.3) 1 0.661–4.126 0.283
No microcalcifications 11 (57.9) 171 (73.7) 1.651
Density 12 (63.2) 165 (71.1) 1 0.375–2.450 0.929
No density 7 (36.8) 67 (28.9) 0.958
Mammographic size p2cm 9 (47.4) 128 (55.2) 0.861 0.349–2.125 0.745
Mammographic size 42cm 10 (52.6) 104 (44.8) 1
BCS 13 (68.4) 50 (21.6) 10.328 2.907–36.693 o0.001
BCS+XRT 3 (15.8)) 55 (23.7) 2.925 0.566–15.112 0.200
Mastectomy 3 (15.8) 127 (54.7) 1
Axillary staging surgery 1 (5.3) 27 (11.6) 0.533 0.071–4.012 0.541
No axillary staging surgery 18 (94.7) 205 (88.4) 1
Positive margins (o1mm) 5 (26.3) 13 (5.6) 4.790 1.696–13.531 0.003
Negative margins (X1mm) 14 (73.7) 219 (94.4) 1
Pathological size p2cm 12 (63.2) 107 (46.1) 2.166 0.849–5.524 0.106
Pathological size 42cm 7 (37.8) 125 (53.9) 1
Grade 1 3 (15.8) 43 (18.5) 0.778 0.203–3.053 0.730
Grade 2 9 (47.4) 96 (41.4) 1.253 0.466–3.365 0.655
Grade 3 7 (36.8) 93 (40.1) 1
Guidelines  12 (73.2) 67 (28.9) 4.339 1.695–11.108 0.002
Guidelines+ 7 (36.8) 165 (71.1) 1
1992–1995 5 (26.3) 47 (20.2) 1.254 0.272–5.776 0.772
1996–1999 11 (57.9) 83 (35.8) 1.976 0.526–7.421 0.313
2000–2003 3 (15.8) 102 (44.0) 1
LR+¼local recurrence; age is depicted as the median value; HR¼hazard ratio; CI¼confidence interval; FNAC¼fine-needle aspiration cytology; SCNB¼stereotactic large core
needle biopsy; BCS¼breast-conserving surgery; BCS+XRT¼breast-conserving surgery and radiotherapy; pathological grade according to EPWG classification;
guidelines+¼treatment according to CCCN guidelines.
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DCIS were developed in 1992 and subsequently they have been
updated every 2 or 3 years. The present study was undertaken to
investigate the effect of compliance with the existing guidelines on
LR-free survival, and it clearly demonstrates that treatment
according to these guidelines leads to a better outcome.
Owing to the change of guidelines over time, study period can be
considered as a proxy for the nature of guidelines. However, since
the study period is not a significant factor in the Cox analysis, the
present study should not be considered to be a validation of the
guidelines. In addition, the LR rate did not improve over time,
since the events and follow-up of patients treated, especially in the
third study period, are insufficient to show differences. Compli-
ance with the guidelines is the only predictive factor, whereas there
is no indicative effect of the nature of the guidelines on outcome.
Other well-known risk factors for LR have been included in the
study and they did not prove to be related with LR. Therefore, it
can be concluded that there were no other factors in the group not
treated according to the guidelines that could have led to their
poorer outcome.
Physicians who carry out the treatment according to the
guidelines often take a special interest in breast cancer, and they
usually work in multidisciplinary teams. It is most likely that the
positive effect of the guidelines on disease-free survival could be
explained by this practice. It has already been demonstrated that
surgeon workload is associated with survival from breast cancer
(Stefoski Mikeljevic et al, 2003). If physicians are exposed to a high
case volume of patients with DCIS, and if they follow the guidelines
and work in multidisciplinary teams, it is plausible that they will be
aware of the existing literature covering the whole process of
diagnostic work-up, treatment and follow-up. This practice should
result in better quality of care and an improvement in outcome.
Few data exist regarding outcome differences associated with
deviation from clinical guidelines. Institutional validation of breast
cancer treatment guidelines in Florida reported no effect from
compliance with the guidelines on 5-year survival, but there was a
Table 2 Predictors of local recurrence (Cox’s regression, multivariate
analysis)
Predictors of local recurrence HR 95% CI P-value
BCS 7.842 2.126–28.926 0.002
BCS+XRT 2.432 0.471–12.552 0.085
Mastectomy 1
Deviation from the guidelines 2.778 0.982–6.781 0.041
Compliance with the guidelines 1
BCS¼breast-conserving surgery; HR¼hazard ratio; CI¼confidence interval;
BCS+XRT¼breast-conserving surgery and radiotherapy. Regression analysis by
elimination of variables in a stepwise manner. As a control for unmeasured
differences in the study period, due to changes in guidelines over time, the study
period was added as a factor in the analysis.
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Figure 1 (A) Local recurrence-free survival in all patients who were
treated according to the guidelines (guidelinesþ) and in all patients who
were not treated according to the guidelines (guidelines ). (B) The 5-year
local recurrence-free survival after BCS in patients who were treated
according to the guidelines (guidelinesþ) and in patients who were not
treated according to the guidelines (guidelines ).
Table 3 Clinical characteristics of patients of the entire region of the
North Netherlands (CCCN population) and the two-hospital sample
Clinical
characteristics
CCCN
population
(n¼1389)
Two-hospital
sample (n¼251) v
2 P-value
Mean age (years)
(range)
60 (22–98) 57 (32–85) — —
Screen detected
Yes 625 (45.0) 122 (48.6) 1.12 0.291
No 764 (55.0) 129 (51.4)
Surgery
BCS 525 (43.0) 121 (48.2) 2.30 0.130
Mastectomy 696 (57.0) 130 (51.8)
Unknown 168 0
Axillary surgery
ALND 240 (19.7) 12 (4.8) 32.64 o0.001
SNB 59 (4.8) 16 (6.4)
No axillary 922 (75.5) 223 (88.8)
Surgery
Unknown 168 0
Radiotherapy
Yes 292 (55.6) 58 (48.0) 2.34 0.126
No 233 (44.4) 63 (52.0)
BCS¼breast-conserving surgery; ALND¼axillary lymph node dissection;
SNB¼sentinel node biopsy. Numbers between parentheses are percentages. Age
is depicted as median value.
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(Minter et al, 2001). The above-mentioned study lacked statistical
power to detect any small difference in overall 5-year survival
between the groups. Furthermore, LR-free survival was not studied
and patients with DCIS were excluded. In the systemic adjuvant
treatment of patients with breast cancer, Olivotto et al (1994)
demonstrated that improvements in disease-free survival and
overall survival, noted during the time period of guideline
implementation, were similar to those observed in clinical trials.
The causality could not be demonstrated, but it was suggested
that the improvements in disease-free survival were the result of
operating within the guidelines.
Deviation from the guidelines automatically results in under- or
overtreatment of patients. If patients have been undertreated, their
prognosis is thought to be worse than that of patients who have
been treated appropriately. Overtreatment leads to unnecessary
procedures and overshooting the mark. The inappropriately
treated population in the present study (n¼79) consisted of 49
patients (62%) who had been undertreated, and 30 patients (38%)
who had been overtreated. Under- or overtreatment was not
associated with LR (unpublished data).
In the 12-year period 1992–2003, the guidelines of treatment of
patients with DCIS have evolved, along with new evidence from
studies and trials on this disease. If the most recent CCCN
guidelines (Table 4) are compared with other guidelines (Rutgers
et al, 2001, Olivotto et al, 2001; Morrow et al, 2002; The
Association of Breast Surgery, 2005), conference reports (Schwartz
et al, 2000; Senn et al, 2003) and review articles (Mokbel, 2003;
Sakorafas and Farley, 2003; Burstein et al, 2004), there is a high
degree of consensus between all these documents. Chest wall
radiation for a positive margin after simple mastectomy is not
mentioned in other guidelines. The administration of tamoxifen
after BCS with radiotherapy (in oestrogen-receptor-positive
patients) has so far not been issued, and this policy has not been
followed in the two-hospital sample either. The addition of
tamoxifen to the guidelines might help reduce the incidence of
LRs.
The proportion of patients in the two-hospital sample who
had been treated by simple mastectomy (52%) was similar to
the proportion of patients in the entire region of the North
Netherlands (57%). This percentage approximates the reports from
earlier periods in the southeast Netherlands (1984–1989, 53%;
Voogd et al, 2000) and from North Carolina (1990–2000, 52%;
Kotwall et al, 2003), but is much higher than that reported in
recent studies from California, Australia and Geneva (38, 24 and
22%, respectively; Morris et al, 2000; Verkooijen et al, 2002;
Kricker and Armstrong, 2004). This indicates that mastectomy has
played a dominant role in the treatment of patients with DCIS in
the North Netherlands during the study period when compared
with other studies. Axillary lymph node staging procedures
(including sampling and SNB) had been performed on 299
(25%) out of 1221 patients (in 168 patients it was unknown
whether axillary surgery had been performed). While this
percentage was higher than in the subgroup of the two-hospital
Table 4 Summary of recent clinical guidelines and recommendations in the management of DCIS
Guidelines BCS Mastectomy Axillary staging Radiotherapy Hormonal therapy
EUSOMA
(Rutgers et al,
2001)
BCS is advised in the
case of small areas of
DCIS (o3cm)
Mastectomy is advised in the
case of large areas of DCIS
(43cm)
Axillary staging is not
recommended
Whole-breast irradiation is
optional after BCS
—
Condition: free margins Mastectomy is advised in the
case of persistent positive
margins after BCS
SCCPG
(Olivotto et al,
2001)
BCS is advised in the
case of small areas of
DCIS
Mastectomy is advised in the
case of large or diffuse areas
of DCIS
Axillary staging is not
recommended
Whole-breast irradiation is
advised after BCS
Hormonal therapy is
optional after BCS
and XRT
Conditions: cosmetically
acceptable and free
margins
Mastectomy is advised in the
case of persistent positive
margins after BCS
ACR
ACS
CAP
SSO
(Morrow et al,
2002)
BCS is advised in the
case of localised DCIS
and extent p4cm
Mastectomy is advised in the
case of multifocal and diffuse
DCIS
SNB or level I ALND is
advised in the case of large
areas of DCIS requiring
mastectomy
Whole-breast irradiation is
advised after BCS
Hormonal therapy is
optional after BCS
and XRT
Conditions: cosmetically
acceptable and free
margins
Mastectomy is advised in the
case of persistent positive
margins after BCS
CCCN
(Otter, 2003)
BCS has the preference
overmastectomy
Mastectomy is advised in the
case of persistent positive
margins after BCS
SNB is advised in the case
of large areas of DCIS
(X5cm)
Whole-breast irradiation is
advised after BCS
Hormonal therapy is
not recommended
Conditions: cosmetically
acceptable and free
margins
Chest wall irradiation is advised
in the case of a positive
margin after mastectomy
BASO (The
Association of
Breast Surgery,
2005)
— Mastectomy is advised in the
case of extensive
microcalcifications on
mammography
SNB is advised in the case
of extensive tumour, high
grade, palpable mass or mass
on mammography
Whole-breast irradiation is
advised after BCS
—
BCS¼breast-conserving surgery; EUSOMA¼European Society of Mastology; condition¼all the conditions must be met in order to carry out BCS; SCCPG¼Steering
Committee on Clinical Practice Guidelines for the Care and Treatment of Breast cancer; ACR¼American College of Radiology; SNB¼sentinel node biopsy; ACS¼American
College of Surgeons; ALND¼axillary lymph node dissection; CAP¼College of American Pathology; SSO¼Society of Oncology; CCCN¼Comprehensive Cancer Centre
North Netherlands; BASO¼British Association of Surgical Oncology.
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and could be brought down, it is comparable with data from parts
of Australia (18%; Kricker and Armstrong, 2004) and the US
SEER registries (15–34%; Baxter et al, 2004), indicating that, at the
same time, it is acceptable to compare the percentages of our
cohort of patients with DCIS to those of other large cohorts
elsewhere.
Outcome in patients with DCIS was not measured as overall
survival, but as LR-free survival because, in the follow-up period of
the study, only two patients died. It was not possible to establish
whether the two-hospital population under study was representa-
tive of the whole region with regard to pathological size and
margin status after final surgery, or with regard to the number of
LRs. This might yield bias in the sense that other factors associated
with LR-free survival could have been identified had data of the
entire population of patients of the North Netherlands been
known.
In conclusion, the introduction and update of guidelines for the
treatment of patients with DCIS in the CCCN region resulted in a
compliance rate of 68.8% of the patients in the two-hospital sample
and the two-hospital sample was representative for the whole
region. Compliance with the guidelines was an independent
predictor of disease-free survival. These data support the
application of guidelines in the treatment of DCIS and they
emphasise the importance of audit to assess whether guidelines are
being followed.
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